| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000723 | Telomere maintenance | Affects phenotype | PMID:23774483 |
| GO:0001503 | Ossification | Increases phenotype | PMID:25014179 |
| GO:0002024 | Diet induced thermogenesis | Affects phenotype | PMID:25076055 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:24820114; PMID:24968063 |
| GO:0005243 | Gap junction channel activity | Decreases phenotype | PMID:26023933 |
| GO:0006007 | Glucose catabolic process | Decreases phenotype | PMID:29477483 |
| GO:0006021 | Inositol biosynthetic process | Increases phenotype | PMID:29477483 |
| GO:0006094 | Gluconeogenesis | Decreases phenotype | PMID:29477483 |
| GO:0006096 | Glycolytic process | Affects phenotype | PMID:31724279 |
| GO:0006114 | Glycerol biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0006304 | Dna modification | Decreases phenotype | PMID:28659405 |
| GO:0006306 | Dna methylation | Decreases phenotype | PMID:20064773; PMID:28263910; PMID:30207508; PMID:31079544 |
| GO:0006526 | Arginine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0006529 | Asparagine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0006532 | Aspartate biosynthetic process | Increases phenotype | PMID:29477483 |
| GO:0006545 | Glycine biosynthetic process | Affects phenotype | PMID:29477483 |
| GO:0006561 | Proline biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0006592 | Ornithine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:24820114; PMID:24968063 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:15820723 |
| GO:0006979 | Response to oxidative stress | Increases phenotype | PMID:15820723 |
| GO:0007160 | Cell-matrix adhesion | Increases phenotype | PMID:24820114 |
| GO:0007613 | Memory | Decreases phenotype | PMID:16968864 |
| GO:0008219 | Cell death | Increases phenotype | PMID:29477483 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:20623010; PMID:24968063; PMID:25014179 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:29149346; PMID:32949729 |
| GO:0009085 | Lysine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0009086 | Methionine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0009097 | Isoleucine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0009098 | Leucine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0009099 | Valine biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0010424 | Dna methylation on cytosine within a cg sequence | Affects phenotype | PMID:38294233 |
| GO:0019344 | Cysteine biosynthetic process | Affects phenotype | PMID:29477483 |
| GO:0019393 | Glucarate biosynthetic process | Increases phenotype | PMID:29477483 |
| GO:0022602 | Ovulation cycle process | Affects phenotype | PMID:16299097 |
| GO:0031324 | Negative regulation of cellular metabolic process | Increases phenotype | PMID:35413382 |
| GO:0031959 | Mineralocorticoid receptor signaling pathway | Increases phenotype | PMID:29149346 |
| GO:0032715 | Negative regulation of interleukin-6 production | Increases phenotype | PMID:31542660 |
| GO:0032755 | Positive regulation of interleukin-6 production | Increases phenotype | PMID:31542660 |
| GO:0032776 | Dna methylation on cytosine | Affects phenotype | PMID:31682807 |
| GO:0032868 | Response to insulin | Affects phenotype | PMID:25076055 |
| GO:0033148 | Positive regulation of intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:26022396; PMID:26139245 |
| GO:0033610 | Oxalate biosynthetic process | Decreases phenotype | PMID:29477483 |
| GO:0033993 | Response to lipid | Decreases phenotype | PMID:28659405 |
| GO:0034587 | Pirna processing | Increases phenotype | PMID:30207508 |
| GO:0035938 | Estradiol secretion | Increases phenotype | PMID:30817981 |
| GO:0040015 | Negative regulation of multicellular organism growth | Increases phenotype | PMID:31682807 |
| GO:0040029 | Epigenetic regulation of gene expression | Affects phenotype | PMID:30207508 |
| GO:0042427 | Serotonin biosynthetic process | Decreases phenotype | PMID:28263910 |
| GO:0042554 | Superoxide anion generation | Affects phenotype | PMID:31923579 |
| GO:0042593 | Glucose homeostasis | Decreases phenotype | PMID:25076055 |
| GO:0042696 | Menarche | Affects phenotype | PMID:16299097 |
| GO:0043433 | Negative regulation of dna-binding transcription factor activity | Increases phenotype | PMID:26022396 |
| GO:0043651 | Linoleic acid metabolic process | Affects phenotype | PMID:29477483 |
| GO:0045444 | Fat cell differentiation | Increases phenotype | PMID:25014179 |
| GO:0046034 | Atp metabolic process | Affects phenotype | PMID:32949729 |
| GO:0046323 | Glucose import | Affects phenotype | PMID:31923579 |
| GO:0046370 | Fructose biosynthetic process | Affects phenotype | PMID:29477483 |
| GO:0050679 | Positive regulation of epithelial cell proliferation | Decreases phenotype | PMID:28659405 |
| GO:0050847 | Progesterone receptor signaling pathway | Decreases phenotype | PMID:26022396 |
| GO:0050890 | Cognition | Decreases phenotype | PMID:16818570; PMID:16968864; PMID:26414943; PMID:29648420 |
| GO:0051091 | Positive regulation of dna-binding transcription factor activity | Increases phenotype | PMID:26022396 |
| GO:0051882 | Mitochondrial depolarization | Increases phenotype | PMID:31404653 |
| GO:0060612 | Adipose tissue development | Increases phenotype | PMID:25076055; PMID:31746186 |
| GO:0061744 | Motor behavior | Affects phenotype | PMID:29648420 |
| GO:0071514 | Genomic imprinting | Affects phenotype | PMID:30005188 |
| GO:0072593 | Reactive oxygen species metabolic process | Increases phenotype | PMID:24820114; PMID:24968063; PMID:31724279; PMID:31923579 |
| GO:0080182 | Histone h3-k4 trimethylation | Affects phenotype | PMID:38294233 |
| GO:0098609 | Cell-cell adhesion | Decreases phenotype | PMID:24820114 |
| GO:0098781 | Ncrna transcription | Increases phenotype | PMID:30207508 |
| GO:1900222 | Negative regulation of amyloid-beta clearance | Increases phenotype | PMID:34045954 |
| GO:1900223 | Positive regulation of amyloid-beta clearance | Affects phenotype | PMID:34045954 |
| GO:1900535 | Palmitic acid biosynthetic process | Increases phenotype | PMID:29477483 |
| GO:1901142 | Insulin metabolic process | Affects phenotype | PMID:31746186 |
| GO:1901538 | Changes to dna methylation involved in embryo development | Affects phenotype | PMID:30005188 |
| GO:1990349 | Gap junction-mediated intercellular transport | Decreases phenotype | PMID:35413382 |
| GO:2000610 | Negative regulation of thyroid hormone generation | Increases phenotype | PMID:31284115 |
| GO:2001057 | Reactive nitrogen species metabolic process | Affects phenotype | PMID:31923579 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.